All In Biotech

Drug Trial Radar · NCT00372593

Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia

A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults

Last checked: Nov 20, 2026Latest source record: Mar 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,070 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,070

Actual

Start

Aug 2006

Primary completion

Aug 2013

Study completion Sep 30, 2020

Sponsor

Lead sponsor
Children's Oncology GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Sep 7, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, up to 29 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as gemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving combination chemotherapy together with gemtuzumab may kill more cancer cells. It is not yet known whether combination chemotherapy is more effective with or without gemtuzumab in treating patients with newly diagnosed acute myeloid leukemia. PURPOSE: This randomized phase III trial is studying combination chemotherapy and gemtuzumab to see how well they work compared with combination chemotherapy alone in treating young patients with newly diagnosed acute myeloid leukemia.

Conditions

  • Leukemia

Interventions

  • asparaginaseDrug

    Given intramuscularly

  • cytarabineDrug

    Given IV

  • daunorubicin hydrochlorideDrug

    Given IV over 6 hours

  • etoposideDrug

    Given IV over 1-4 hours

  • gemtuzumab ozogamicinDrug

    Given IV over 2 hours

  • mitoxantrone hydrochlorideDrug

    Given IV over 1 hour

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free Survival at 3 YearsTime frame: Time from study entry to time of induction failure, relapse, or death, assessed at 3 years
  2. Overall Survival at 3 YearsTime frame: Time from study entry, assessed at 3 years

Locations

198 sites in 6 countries. Site status is shown where the registry gives one.

  • UAB Comprehensive Cancer Center

    Birmingham, Alabama

  • University of South Alabama Mitchell Cancer Institute

    Mobile, Alabama

  • Banner Desert Medical Center

    Mesa, Arizona

  • Phoenix Children's Hospital

    Phoenix, Arizona

  • Arizona Cancer Center at University of Arizona Health Sciences Center

    Tucson, Arizona

  • Arkansas Cancer Research Center at University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Southern California Permanente Medical Group

    Downey, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Loma Linda University Cancer Institute at Loma Linda University Medical Center

    Loma Linda, California

  • Childrens Hospital Los Angeles

    Los Angeles, California

  • Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center

    Los Angeles, California

  • Jonsson Comprehensive Cancer Center at UCLA

    Los Angeles, California

  • Children's Hospital Central California

    Madera, California

  • Children's Hospital and Research Center Oakland

    Oakland, California

  • Kaiser Permanente Medical Center - Oakland

    Oakland, California

  • Children's Hospital of Orange County

    Orange, California

  • Sutter Cancer Center

    Sacramento, California

  • University of California Davis Cancer Center

    Sacramento, California

  • Rady Children's Hospital - San Diego

    San Diego, California

  • UCSF Helen Diller Family Comprehensive Cancer Center

    San Francisco, California

  • Santa Barbara Cottage Children's Hospital

    Santa Barbara, California

  • Jonathan Jaques Children's Cancer Center at Miller Children's Hospital

    Torrance, California

  • Children's Hospital Center for Cancer and Blood Disorders

    Aurora, Colorado

  • Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center

    Farmington, Connecticut

  • Yale Cancer Center

    New Haven, Connecticut

  • Alfred I. duPont Hospital for Children

    Wilmington, Delaware

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Walter Reed Army Medical Center

    Washington D.C., District of Columbia

  • Broward General Medical Center Cancer Center

    Fort Lauderdale, Florida

  • Lee Cancer Care of Lee Memorial Health System

    Fort Myers, Florida

  • University of Florida Shands Cancer Center

    Gainesville, Florida

  • Memorial Cancer Institute at Memorial Regional Hospital

    Hollywood, Florida

  • Nemours Children's Clinic

    Jacksonville, Florida

  • University of Miami Sylvester Comprehensive Cancer Center - Miami

    Miami, Florida

  • Miami Children's Hospital

    Miami, Florida

  • Baptist-South Miami Regional Cancer Program

    Miami, Florida

  • Florida Hospital Cancer Institute at Florida Hospital Orlando

    Orlando, Florida

  • M.D. Anderson Cancer Center at Orlando

    Orlando, Florida

  • Nemours Children's Clinic - Orlando

    Orlando, Florida

  • Sacred Heart Cancer Center at Sacred Heart Hospital

    Pensacola, Florida

Showing 40 of 198 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.